grant
Project 1
Organization UNIVERSITY OF VIRGINIALocation CHARLOTTESVILLE, UNITED STATESPosted 1 Sept 2025Deadline 31 Aug 2030
NIHUS FederalResearch GrantFY202521+ years old5 AZC5-AC5-Aza-cytidine5-AzacytidineAML - Acute Myeloid LeukemiaAZCAblationAcute Myeloblastic LeukemiaAcute Myelocytic LeukemiaAcute Myelogenous LeukemiaAcute leukemiaAdultAdult HumanAffectAnabolismAzacitidineAzacytidineBindingBinding SitesBioenergeticsBiological MarkersBiophysicsCRISPR approachCRISPR based approachCRISPR methodCRISPR methodologyCRISPR techniqueCRISPR technologyCRISPR toolsCRISPR-CAS-9CRISPR-based methodCRISPR-based techniqueCRISPR-based technologyCRISPR-based toolCRISPR/CAS approachCRISPR/Cas methodCRISPR/Cas technologyCRISPR/Cas9CRISPR/Cas9 technologyCas nuclease technologyCell BodyCell Communication and SignalingCell CompartmentationCell CompartmentationsCell DeathCell LineCell SignalingCell SurvivalCell ViabilityCell modelCellLineCellsCellular modelCeramidesCessation of lifeClinicalClustered Regularly Interspaced Short Palindromic Repeats approachClustered Regularly Interspaced Short Palindromic Repeats methodClustered Regularly Interspaced Short Palindromic Repeats methodologyClustered Regularly Interspaced Short Palindromic Repeats techniqueClustered Regularly Interspaced Short Palindromic Repeats technologyCollaborationsCombining SiteComputer ModelsComputerized ModelsCoupledDataDeathDevelopmentDiagnosisDisease OutcomeDrug Metabolic DetoxicationDrug Metabolic DetoxificationEarly-Stage Clinical TrialsEnzyme GeneEnzymesGEM modelGEMM modelGenetically Engineered MouseGenetics-MutagenesisGoalsHexose Monophosphate ShuntIn VitroInositide PhospholipidsInositol PhosphoglyceridesInositol PhospholipidsIntermediary MetabolismIntracellular Communication and SignalingInvestigatorsLinkLipidsMetabolicMetabolic Drug DetoxicationsMetabolic ProcessesMetabolismMetabolism of Toxic AgentsMethodsMitochondriaModelingMolecularMolecular InteractionMutagenesisMutagenesis Molecular BiologyOrganellesOxidative PhosphorylationOxidative Phosphorylation PathwayP01 MechanismP01 ProgramPLA2G4APLA2G4A genePathway interactionsPatientsPentose Phosphate PathwayPentose Phosphate ShuntPentose ShuntPentosephosphate PathwayPentosephosphate ShuntPhase 1 Clinical TrialsPhase I Clinical TrialsPhosphatesPhosphatidyl InositolPhosphatidylinositolsPhosphoinositidesPhospholipase A2 Group IVAPhospholipase A2, Cytosolic, Calcium-Dependent, AlphaPre-Clinical ModelPrecision therapeuticsPreclinical ModelsProgram Project GrantProgram Research Project GrantsProteomicsPtdInsReactive SiteRefractoryRelapseResearchResearch PersonnelResearch Program ProjectsResearchersResistanceRoleSafetySignal TransductionSignal Transduction SystemsSignalingSphingolipidsStrains Cell LinesSurface Plasmon ResonanceSurvival RateSystemTherapeuticToxic effectToxicitiesTreatment EfficacyTreatment outcomeacute granulocytic leukemiaacute granulocytic leukemia cellacute myeloblastic leukemia cellacute myelocytic leukemia cellacute myelogenous leukemia cellacute myeloid leukemiaacute myeloid leukemia cellacute nonlymphocytic leukemia celladulthoodbio-markersbiologic markerbiological signal transductionbiomarkerbiophysical approachesbiophysical foundationbiophysical methodologybiophysical methodsbiophysical principlesbiophysical sciencesbiophysical techniquesbiosynthesiscPLA2-Alphaceramide 1-phosphateceramide kinasecombinatorialcomputational modelingcomputational modelscomputer based modelscomputerized modelingcultured cell linedetoxificationdevelopmentalgenetically engineered mouse modelgenetically engineered murine modelgenome scalegenome-widegenomewideimprovedin vivoinhibitorinnovateinnovationinnovativeinorganic phosphateintervention efficacykinase inhibitorladakamycinleukemialeukemia treatmentleukemic therapymembermetabolism measurementmetabolomicsmetabonomicsmitochondrialmutantnanoliposomalnanoliposomenecrocytosisnovelpathwaypharmacologicphase I protocolpre-clinicalprecision therapiesprecision treatmentpreclinicalresistantsensorsocial rolestandard of caretargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic efficacytherapeutic targettherapy efficacytoolvirtual
Description preview
PROJECT SUMMARY
Acute myeloid leukemia (AML) has a 5-year survival rate of ~30%. Despite new treatments, these rates have
changed little with virtually all patients developing relapsed/refractory AML. Thus, there is a strong clinical need
to improve treatment outcomes for this disease. In this regard, our P01 team has built the foundational…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click